Tanvex
泰福生技股份有限公司
Tanvex is a Taiwan TWSE-listed biotechnology company; its most advanced asset is TX01 (Approved and commercialized, Chemotherapy-induced neutropenia), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| TX01 | — | Approved and commercialized | Chemotherapy-induced neutropenia | United States, Canada | 2026-04-06 | Company disclosure |
| TX05 | — | BLA resubmission | Breast and gastric cancer | United States | 2026-07-26 | Company disclosure |
Key events
- Business update (company filing)
Related Drugnews articles
No related articles in this language.